Abstract. Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in adenocarcinomas, specifically in non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varying severity is overlooked in long-term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. The patient achieved partial clinical remission but developed drug-induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient’s liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib-induced hepatotoxicity.

Introduction
Gefitinib is a selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), which has come to be the most widely used in advanced non-small cell lung cancer (NSCLC) patients. It is a standard first-line therapy for advanced NSCLC patients harboring somatic EGFR mutations (1).

Case report
A 61-year-old non-smoking Chinese female was admitted to the Affiliated Hangzhou Hospital of Nanjing Medical University (Hangzhou, China) with a repeated cough, expectoration and shortness of breath for >1 month. Chest computed tomography (CT) revealed a mass in the superior lobe of the left lung, encapsulated effusion in the left pleural cavity and left atelectasis (Fig. 1A). Cancer cells had previously been identified in the hydrothorax. A left lung biopsy was completed and histopathological study revealed an adenocarcinoma with bronchoalveolar features. Genetic analysis detected a deletion in exon 19 of the EGFR gene. The diagnosis was left lung cancer pleural metastasis (stage IV). The patient was administered gefitinib (Iressa; 250 mg per day; AstraZeneca, London, UK) as first-line therapy for advanced NSCLC patients harboring somatic EGFR mutations (4).

Previous clinical studies have demonstrated that gefitinib is capable of significantly prolonging progression-free survival (PFS) and improving the quality of life in NSCLC patients carrying EGFR mutations, compared with standard chemotherapy (2-4). Due to its high binding selectivity, the toxicity of gefitinib is relatively low. The most common adverse effects are mild to moderate skin rash, diarrhea and fatigue. However, liver injury of varying severity has also been reported (5-6) and was noted in the current case report. Furthermore, the incidence of increased alanine aminotransferase (ALT) levels is more common in patients harboring somatic EGFR mutations (4,7). The development of a method to effectively utilize the clinical benefit of gefitinib, whilst simultaneously avoiding its hepatotoxicity, is a challenge for oncologists. The current case report presents a favorable clinical outcome of gefitinib rechallenge in a female Chinese NSCLC patient. Written informed consent was obtained from the patient.

Correspondence to: Dr Shenglin Ma, Department of Medical Oncology, Nanjing Medical University, Affiliated Hangzhou Hospital (Hangzhou First People's Hospital), 261 Huansha Road, Hangzhou, Zhejiang 310006, P.R. China
E-mail: mashenglin@medmail.com.cn

Key words: hepatotoxicity, epidermal growth factor, tyrosine kinase inhibitor, adverse drug reactions
The general condition of the patient remained good and disease was stable up to 14 months, in which severe hepatotoxicity was noted, with increased ALT and aspartate aminotransferase levels at 1,130 U/l (grade 4 toxicity) and 629 U/l (grade 3 toxicity), respectively (CTCAE v3.0; Cancer Therapy Evaluation Program, Bethesda, MD, USA). Liver metastasis and other diseases were ruled out and no other medications were administered. As such, elevation of the hepatic enzymes was attributed to gefitinib. Consequently, gefitinib treatment was discontinued and hepatoprotective therapy was carried out. Liver function later improved, with the ALT levels decreasing to 98 and 69 U/l at 6 and 10 weeks following gefitinib discontinuation, respectively (Fig. 2A). However, gefitinib withdrawal for 2 months resulted in disease progression. With regard to gefitinib-induced severe hepatotoxicity, the treatment plan was changed to chemotherapy with pemetrexed and cisplatin for four cycles, with continued hepatoprotective treatment and liver function monitoring. Lab results revealed that liver function deteriorated following each chemotherapy cycle, with ALT levels not exceeding 198 U/l, but was quickly restored to normal levels (Fig. 2B). CT examination suggested that the lesion of the left lung mildly decreased and an evaluation of disease stability was made. As the liver function recovered, gefitinib was re-administered at the same dosage, following discontinuation for 3 months. At the time of writing, the patient had been re-administered with gefitinib for 6 months. The disease remains well-controlled and hepatic enzyme levels have remained normal.

Discussion

EGFR-TKIs inhibit TK self-phosphorylation by competing with adenosine triphosphate for the binding sites of the TK domain, thereby blocking the transmission of downstream signaling and inhibiting tumor cell proliferation (8). It has been suggested that advanced NSCLC patients harboring somatic EGFR mutations exhibit a higher response rate and longer PFS when treated with a TKI (gefitinib or erlotinib), compared with chemotherapy (2,9). However, drug-induced hepatotoxicity can be a potential hindrance in the clinical administration of gefitinib. In several phase III clinical trials, it was reported that 20‑30% of NSCLC patients with unknown EGFR mutation status developed hepatic enzyme elevation while receiving gefitinib treatment. Among them, grade 3‑4 hepatotoxicity was observed in 3‑5% of cases, with a maximum incidence of 11.33% (7,10,11). In NSCLC patients harboring identified EGFR mutations, the incidence of gefitinib-induced hepatic injury was even greater, with 50‑70% of patients developing drug-induced liver toxicity and 16‑26% of these with grade 3‑4 injury (3,4). However, long-term administration in NSCLC is required to effectively control the disease and premature drug discontinuation will increase the risk of tumor progression.

To date, only a small number of studies on TKI-induced hepatotoxicity have been reported, which are retrospective studies with small sample sizes or case reports. A number of these suggest that gefitinib-induced liver injury may be prevented through adjusting the dosage and schedule or altering...
the treatment strategy, for example switching to another TKI, such as erlotinib. Seki et al reported a case of a 61-year-old Japanese female with lung adenocarcinoma who developed gefitinib-induced grade 2/3 liver injury following two cycles of gefitinib administration. The drug was discontinued despite complete remission of primary and metastatic tumors. However, when the patient received gefitinib at a volume of 250 mg once every 5 days, liver function was maintained at grade 1 and the disease was controlled (12). Additionally, Ku et al presented two patients with NSCLC who successfully switched to treatment with another TKI, erlotinib, following development of grade 2/3 gefitinib-induced hepatotoxicity (6). Furthermore, one patient demonstrated a long and near-complete response from erlotinib. In the current case report, the patient developed grade 4 liver injury during the initial gefitinib treatment. Four sequential cycles of chemotherapy were immediately administered following withdrawal of gefitinib, and the subsequent gefitinib rechallenge, combined with liver-protective therapy, was carried out following restoration of liver function. At the time of writing, gefitinib re-administration had continued for six months. The patient tolerated the initial dosage and schedule without any detectable hepatic injury, and presented good disease control with a relatively improved clinical outcome compared with the previous report (12). Sequential chemotherapy and subsequent reinitiated gefitinib treatment may be a potential new strategy for gefitinib-induced hepatotoxicity.

In conclusion, the current case report indicates that routine monitoring of liver enzymes and active hepatoprotective treatment are essential for patients receiving long-term gefitinib administration. With drug-induced liver injury, early withdrawal of gefitinib medication in NSCLC patients, without subsequent gefitinib rechallenge, is not recommended. Future studies focusing on the mechanism of TKI-induced hepatotoxicity, as well as the relationship between genetic factors and the diverse toxic effects of TKIs in the general population, are likely to promote the application of EGFR-TKIs in NSCLCs.

References
1. Ettinger DS, Akerley W, Borghaei H, et al: Non-small cell lung cancer. J Natl Compr Canc Netw 10: 1236-1271, 2012.
2. Mok TS, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
3. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboursing mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
4. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
5. Chen J, Gu R, Wang Q, et al: Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie 35: 509-513, 2012.
6. Ku GY, Chopra A and Lopes Gde L Jr: Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 70: 223-225, 2010.
7. Han JY, Park K, Kim SW, et al: First-SIGNAL: first-line single-agent irressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30: 1122-1128, 2012.
8. Von Pawel J: Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 91: E70-E76, 2004.
9. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
10. Zhang L, Ma S, Song X, et al: Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 13: 466-475, 2012.
11. Takeda K, Hida T, Sato T, et al: Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28: 753-760, 2010.
12. Seki N, Uematsu K, Shibakuki R and Eguchi K: Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 24: 3213-3214, 2006.